Avacta Group PLC Fundamentals Datasheet and Stock Analysis


Avacta Group PLC Company Logo
Avacta Group plc is a biotechnology company. Avacta's focus is on its proprietary Affimer technology which is an engineered alternative to antibodies that has application in Life Sciences for diagnostics, therapeutics and general research and development. Affimer technology has been designed to address performance limitations of antibodies. Affimer technology is based on a small protein that can be generated to bind with specificity and affinity to a range of targets to enable diagnostics, research assays and therapeutics. Avacta has a pre-clinical therapeutic development programme with an in-house focus on immuno-oncology and bleeding disorders as well as partnered development programmes. Avacta is commercialising non-therapeutic Affimer reagents through licensing to developers of life sciences research tools and diagnostics.

  • Current Price:
  • Industry:
     Health Care
  • Sector:
     Health Care
  • ISIN:
  • Market Sector:
  • Main Indices:
  • Country of register:
     Great Britain
  • Currency:
  • Shares in Issue:
  • Market Cap:
  • Date Listed:
Operation Breakdown
Geographical - by origin (turnover)
Product (turnover)


Activity Data Not Available

Company Information

CEO: Alastair Smith  CFO: Tony Peter Gardiner  Non-Executive Director: Trevor Nichols, Sam Williams Alan John Aubrey  Non-Executive Chairman: Eliot Forster  Senior Independent Director: Mike Owen  Chief Medical Officer: Jose Saro  

  • Registrars:
     Capita Registrars
  • Address:
     Unit 20, Ash Way, Thorp Arch Estate, Wetherby, United Kingdom
  • Phone:
     +44 (0)84 4414 0452
  • Website:
Composite Ranking: 63
Historic EPS Ranking: 64
Forecast EPS Ranking: 39
Price Relative Strength: 
Industry Strength: H
SMR Ranking: E
ROCE Ranking: F
Accumulation/Dist: B
Mkt Accumulation/Dist: C
Unbroken Annual EPS: E
Unbroken Interim EPS: E
PEG Current Ranking: A
PEG Forecast Ranking: A
PE Current Ranking: A
PE Forecast Ranking: A
Margin Current Ranking: H
Margin Forecast Ranking: H
Add Indicator


Takes the average of data over a period of time, and migrates the period across the data series one data point at a time. This formula smooths a data series and makes analysing volatile data easier.
Operating Profit/(loss)£m(1.64)(1.87)(2.05)(5.57)(5.66)(7.98)(10.43)£m0.000.00
Profit Before Tax£m(1.60)(1.85)(2.02)(5.54)(5.57)(7.89)(10.39)£m(10.46)(9.64)
Profit After Tax£m(1.11)(1.52)(1.47)(4.89)(4.65)(6.37)(8.83)£m0.000.00
Profit After Tax (from discontinued operations)£m0.000.00(0.02)(5.10)£m0.000.00
Overall Profit for the Period£m(1.11)(1.52)(1.49)(9.99)(4.65)(6.37)(8.83)£m0.000.00
EPS Growth%
Earnings Per Sharep(4.00)(5.00)(4.00)(10.00)(6.86)(9.77)(13.49)p(7.51)(6.61)
Op. Cash Flow P/Sp(0.01)(4.36)(2.00)(5.06)(6.25)(6.51)(8.36)£0.000.00
Cash Flow P/S Grth%
Net Cash Flow P/Sp0.£0.000.00
Capital Exp P/S££0.000.00
Tax Rate%
P/E Ratiox0.
P/E Growth££0.000.00
Turnover Per Share££0.000.00
Pre-Tax Profit / Share£(0.03)£0.000.00
Operating Margin%0.00(69.37)(126.39)(307.73)(260.83)(292.31)(377.90)%0.000.00
Mkt Cap£m51.9897.57122.91164.6697.9893.9229.80£m0.000.00
Dividend Per Sharep0.
DPS Growth%
Dividend Yield%
Dividend Coverx0.
Shareholder Funds£m16.9615.5528.8419.1335.8629.8921.41£m0.000.00
Net Borrowings£m(4.19)(0.58)(11.48)(7.33)(9.52)(9.17)(5.22)£m0.000.00
Net Assets£m16.9615.5528.8419.1335.8629.8921.41£m0.000.00
Net Assets P/S££0.000.00
Latest Forecast
Div Yield0.0%0.0%
Div Cover0.0%0.0%
Op Margin-377.9%-318.4%
Director Deals
Traded Action Notifier Price Amount Value
31-Dec-18BuyTony Peter Gardiner30.50p8,196,632,499.78
30-Jul-18BuyEliot Forster25.00p120,000,330,000
30-Jul-18PlacingAlan John Aubrey25.00p80,000,320,000
30-Jul-18PlacingTrevor Nichols25.00p40,000,310,000
30-Jul-18PlacingAlastair Smith25.00p40,000,310,000
09-Apr-18BuyMichael Scott Albin36.25p10,345,633,750.06
09-Apr-18BuyMichael Scott Albin36.25p 10,345£3,750.06
13-Mar-18BuyAlastair Smith41.92p35,800,315,007.36
13-Mar-18BuyAlastair Smith41.92p 35,800£15,007.36
04-Jan-18BuyMichael Scott Albin64.60p5,805,633,750.03
First PagePrev PageNext Page  Rows per page
116m    Major: 51%    Director: 1%
Notifier Holding Value
Alastair Smith646,309ê,610.16
Alan John Aubrey271,334b,494.24
Tony Peter Gardiner150,0006,450
Eliot Forster120,000+,560
Trevor Nichols75,000,225
  Rows per page
Gearing & Cover
News Title Date Time Source
Issue of Equity08-Mar-1912:14RNS
Moderna Exercises Exclusive Product License Option04-Feb-1907:00RNS
Director Appointment28-Jan-1907:00RNS
Result of Annual General Meeting21-Jan-1915:40RNS
AGM Business Update and Notice of Results21-Jan-1907:00RNS
Share Incentive Plan/Issue of Equity18-Jan-1917:08RNS
Change of accounting reference date18-Jan-1910:00RNS
Holding(s) in Company09-Jan-1911:06RNS
Director/PDMR Shareholdings07-Jan-1914:50RNS
Holding(s) in Company03-Jan-1908:56RNS
First PagePrev PageNext Page  Rows per page
Broker Opinion
Date Broker Name Rec Price Old Price Target New Price Target Broker Change
18-May-15Numis SecuritiesBuy1.05p1.50p1.70pReiteration
12-Feb-15Panmure GordonBuy0.77p1.75p1.75pReiteration
09-Aug-11Merchant SecuritiesBuy0.81p1.00p0.00pReiteration
  Rows per page

This functionality requires you to login

Click here to login
Or register for a new account